Confirmation and quantitation of human papillomavirus type 52 by Roche Linear Array© using HPV52-specific TaqMan© E6/E7 quantitative real-time PCR

Morgan Marks, Swati B. Gupta, Kai Li Liaw, Esther Kim, Amha Tadesse, Francois Coutlee, Somchai Sriplienchan, David D Celentano, Patti E. Gravitt

Research output: Contribution to journalArticle

Abstract

Human papillomavirus type 52 is highly prevalent in Asia and Africa and accounts for 2-3% of total cervical cancer burden worldwide. The Roche Molecular Systems HPV Linear Array© (RMS-LA©) uses multiple type (i.e. mixed) probes to detect DNA from HPV 52 infection which limits the assay's ability to determine HPV 52 status in the presence of HPV 33, 35, or 58 infection. This report presents a simple to use and highly reproducible HPV 52 type-specific quantitative real-time PCR (RT-PCR) assay based on Taqman© chemistry for detection and quantification of HPV 52 DNA from cervical swab specimens. Mixed probe positive cervical swab specimens collected from rural and urban women in Thailand (n = 68) were used to determine assay agreement and differences in HPV 52 DNA viral load across cytological diagnosis. Forty-eight specimens were determined to be HPV 52 positive by RMS-LA© with 94% (n = 45) confirmed positive by Taqman© assay (kappa: 0.86, 95% CI: 0.74, 0.99). Higher median viral load was observed among women with a Pap diagnosis of >=ASCUS vs. normal/inflammation (8510 copies/1000 cell equivalents vs. 279 copies/1000 cell equivalents, p <0.05). Accurate ascertainment of infection status is important in understanding HPV 52's role in the etiology of cervical cancer as well as for the development of type-specific vaccines.

Original languageEnglish (US)
Pages (from-to)152-156
Number of pages5
JournalJournal of Virological Methods
Volume156
Issue number1-2
DOIs
StatePublished - Mar 2009

Fingerprint

Real-Time Polymerase Chain Reaction
Viral Load
Uterine Cervical Neoplasms
DNA
Infection
Thailand
Vaccines
Inflammation
Atypical Squamous Cells of the Cervix

Keywords

  • Genotype
  • Human papillomavirus type 52
  • PCR
  • Taqman
  • Thailand

ASJC Scopus subject areas

  • Virology

Cite this

Confirmation and quantitation of human papillomavirus type 52 by Roche Linear Array© using HPV52-specific TaqMan© E6/E7 quantitative real-time PCR. / Marks, Morgan; Gupta, Swati B.; Liaw, Kai Li; Kim, Esther; Tadesse, Amha; Coutlee, Francois; Sriplienchan, Somchai; Celentano, David D; Gravitt, Patti E.

In: Journal of Virological Methods, Vol. 156, No. 1-2, 03.2009, p. 152-156.

Research output: Contribution to journalArticle

Marks, Morgan ; Gupta, Swati B. ; Liaw, Kai Li ; Kim, Esther ; Tadesse, Amha ; Coutlee, Francois ; Sriplienchan, Somchai ; Celentano, David D ; Gravitt, Patti E. / Confirmation and quantitation of human papillomavirus type 52 by Roche Linear Array© using HPV52-specific TaqMan© E6/E7 quantitative real-time PCR. In: Journal of Virological Methods. 2009 ; Vol. 156, No. 1-2. pp. 152-156.
@article{4403b23559bb4f36b32094ec855b7d2a,
title = "Confirmation and quantitation of human papillomavirus type 52 by Roche Linear Array{\circledC} using HPV52-specific TaqMan{\circledC} E6/E7 quantitative real-time PCR",
abstract = "Human papillomavirus type 52 is highly prevalent in Asia and Africa and accounts for 2-3{\%} of total cervical cancer burden worldwide. The Roche Molecular Systems HPV Linear Array{\circledC} (RMS-LA{\circledC}) uses multiple type (i.e. mixed) probes to detect DNA from HPV 52 infection which limits the assay's ability to determine HPV 52 status in the presence of HPV 33, 35, or 58 infection. This report presents a simple to use and highly reproducible HPV 52 type-specific quantitative real-time PCR (RT-PCR) assay based on Taqman{\circledC} chemistry for detection and quantification of HPV 52 DNA from cervical swab specimens. Mixed probe positive cervical swab specimens collected from rural and urban women in Thailand (n = 68) were used to determine assay agreement and differences in HPV 52 DNA viral load across cytological diagnosis. Forty-eight specimens were determined to be HPV 52 positive by RMS-LA{\circledC} with 94{\%} (n = 45) confirmed positive by Taqman{\circledC} assay (kappa: 0.86, 95{\%} CI: 0.74, 0.99). Higher median viral load was observed among women with a Pap diagnosis of >=ASCUS vs. normal/inflammation (8510 copies/1000 cell equivalents vs. 279 copies/1000 cell equivalents, p <0.05). Accurate ascertainment of infection status is important in understanding HPV 52's role in the etiology of cervical cancer as well as for the development of type-specific vaccines.",
keywords = "Genotype, Human papillomavirus type 52, PCR, Taqman, Thailand",
author = "Morgan Marks and Gupta, {Swati B.} and Liaw, {Kai Li} and Esther Kim and Amha Tadesse and Francois Coutlee and Somchai Sriplienchan and Celentano, {David D} and Gravitt, {Patti E.}",
year = "2009",
month = "3",
doi = "10.1016/j.jviromet.2008.10.013",
language = "English (US)",
volume = "156",
pages = "152--156",
journal = "Journal of Virological Methods",
issn = "0166-0934",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Confirmation and quantitation of human papillomavirus type 52 by Roche Linear Array© using HPV52-specific TaqMan© E6/E7 quantitative real-time PCR

AU - Marks, Morgan

AU - Gupta, Swati B.

AU - Liaw, Kai Li

AU - Kim, Esther

AU - Tadesse, Amha

AU - Coutlee, Francois

AU - Sriplienchan, Somchai

AU - Celentano, David D

AU - Gravitt, Patti E.

PY - 2009/3

Y1 - 2009/3

N2 - Human papillomavirus type 52 is highly prevalent in Asia and Africa and accounts for 2-3% of total cervical cancer burden worldwide. The Roche Molecular Systems HPV Linear Array© (RMS-LA©) uses multiple type (i.e. mixed) probes to detect DNA from HPV 52 infection which limits the assay's ability to determine HPV 52 status in the presence of HPV 33, 35, or 58 infection. This report presents a simple to use and highly reproducible HPV 52 type-specific quantitative real-time PCR (RT-PCR) assay based on Taqman© chemistry for detection and quantification of HPV 52 DNA from cervical swab specimens. Mixed probe positive cervical swab specimens collected from rural and urban women in Thailand (n = 68) were used to determine assay agreement and differences in HPV 52 DNA viral load across cytological diagnosis. Forty-eight specimens were determined to be HPV 52 positive by RMS-LA© with 94% (n = 45) confirmed positive by Taqman© assay (kappa: 0.86, 95% CI: 0.74, 0.99). Higher median viral load was observed among women with a Pap diagnosis of >=ASCUS vs. normal/inflammation (8510 copies/1000 cell equivalents vs. 279 copies/1000 cell equivalents, p <0.05). Accurate ascertainment of infection status is important in understanding HPV 52's role in the etiology of cervical cancer as well as for the development of type-specific vaccines.

AB - Human papillomavirus type 52 is highly prevalent in Asia and Africa and accounts for 2-3% of total cervical cancer burden worldwide. The Roche Molecular Systems HPV Linear Array© (RMS-LA©) uses multiple type (i.e. mixed) probes to detect DNA from HPV 52 infection which limits the assay's ability to determine HPV 52 status in the presence of HPV 33, 35, or 58 infection. This report presents a simple to use and highly reproducible HPV 52 type-specific quantitative real-time PCR (RT-PCR) assay based on Taqman© chemistry for detection and quantification of HPV 52 DNA from cervical swab specimens. Mixed probe positive cervical swab specimens collected from rural and urban women in Thailand (n = 68) were used to determine assay agreement and differences in HPV 52 DNA viral load across cytological diagnosis. Forty-eight specimens were determined to be HPV 52 positive by RMS-LA© with 94% (n = 45) confirmed positive by Taqman© assay (kappa: 0.86, 95% CI: 0.74, 0.99). Higher median viral load was observed among women with a Pap diagnosis of >=ASCUS vs. normal/inflammation (8510 copies/1000 cell equivalents vs. 279 copies/1000 cell equivalents, p <0.05). Accurate ascertainment of infection status is important in understanding HPV 52's role in the etiology of cervical cancer as well as for the development of type-specific vaccines.

KW - Genotype

KW - Human papillomavirus type 52

KW - PCR

KW - Taqman

KW - Thailand

UR - http://www.scopus.com/inward/record.url?scp=59949087132&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59949087132&partnerID=8YFLogxK

U2 - 10.1016/j.jviromet.2008.10.013

DO - 10.1016/j.jviromet.2008.10.013

M3 - Article

VL - 156

SP - 152

EP - 156

JO - Journal of Virological Methods

JF - Journal of Virological Methods

SN - 0166-0934

IS - 1-2

ER -